Cargando…

Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody

BACKGROUND: Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selective IL-6...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahirović, Abida, Berlec, Aleš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287920/
https://www.ncbi.nlm.nih.gov/pubmed/35842694
http://dx.doi.org/10.1186/s12934-022-01873-7
_version_ 1784748353837334528
author Zahirović, Abida
Berlec, Aleš
author_facet Zahirović, Abida
Berlec, Aleš
author_sort Zahirović, Abida
collection PubMed
description BACKGROUND: Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selective IL-6 binding activity by displaying IL-6-specific affibody on its surface. RESULTS: Anti-IL-6 affibody (designated as ZIL) was expressed in fusion with lactococcal secretion peptide Usp45 and anchoring protein AcmA. A high amount of ZIL fusion protein was detected on bacterial surface, and its functionality was validated by confocal microscopy and flow cytometry. Removal of IL-6 from the surrounding medium by the engineered L. lactis was evaluated using enzyme-linked immunosorbent assay. ZIL-displaying L. lactis sequestered recombinant human IL-6 from the solution in a concentration-dependent manner by up to 99% and showed no binding to other pro-inflammatory cytokines, thus proving to be highly specific for IL-6. The removal was equally efficient across different IL-6 concentrations (150–1200 pg/mL) that were found to be clinically relevant in IBD patients. The ability of engineered bacteria to capture IL-6 from cell culture supernatant was assessed using immunostimulated human monocytic cell lines (THP-1 and U-937) differentiated into macrophage-like cells. ZIL-displaying L. lactis reduced the content of IL-6 in the supernatants of both cell lines in a concentration-dependent manner by up to 94%. Dose response analysis showed that bacterial cell concentrations of 10(7) and 10(9) CFU/mL (colony forming units per mL) were required for half-maximal removal of recombinant and macrophage-derived IL-6, respectively. CONCLUSION: The ability of ZIL-displaying L. lactis to bind pathological concentrations of IL-6 at common bacterial doses suggests physiological significance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01873-7.
format Online
Article
Text
id pubmed-9287920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92879202022-07-17 Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody Zahirović, Abida Berlec, Aleš Microb Cell Fact Research BACKGROUND: Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selective IL-6 binding activity by displaying IL-6-specific affibody on its surface. RESULTS: Anti-IL-6 affibody (designated as ZIL) was expressed in fusion with lactococcal secretion peptide Usp45 and anchoring protein AcmA. A high amount of ZIL fusion protein was detected on bacterial surface, and its functionality was validated by confocal microscopy and flow cytometry. Removal of IL-6 from the surrounding medium by the engineered L. lactis was evaluated using enzyme-linked immunosorbent assay. ZIL-displaying L. lactis sequestered recombinant human IL-6 from the solution in a concentration-dependent manner by up to 99% and showed no binding to other pro-inflammatory cytokines, thus proving to be highly specific for IL-6. The removal was equally efficient across different IL-6 concentrations (150–1200 pg/mL) that were found to be clinically relevant in IBD patients. The ability of engineered bacteria to capture IL-6 from cell culture supernatant was assessed using immunostimulated human monocytic cell lines (THP-1 and U-937) differentiated into macrophage-like cells. ZIL-displaying L. lactis reduced the content of IL-6 in the supernatants of both cell lines in a concentration-dependent manner by up to 94%. Dose response analysis showed that bacterial cell concentrations of 10(7) and 10(9) CFU/mL (colony forming units per mL) were required for half-maximal removal of recombinant and macrophage-derived IL-6, respectively. CONCLUSION: The ability of ZIL-displaying L. lactis to bind pathological concentrations of IL-6 at common bacterial doses suggests physiological significance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01873-7. BioMed Central 2022-07-16 /pmc/articles/PMC9287920/ /pubmed/35842694 http://dx.doi.org/10.1186/s12934-022-01873-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zahirović, Abida
Berlec, Aleš
Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
title Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
title_full Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
title_fullStr Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
title_full_unstemmed Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
title_short Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
title_sort targeting il-6 by engineered lactococcus lactis via surface-displayed affibody
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287920/
https://www.ncbi.nlm.nih.gov/pubmed/35842694
http://dx.doi.org/10.1186/s12934-022-01873-7
work_keys_str_mv AT zahirovicabida targetingil6byengineeredlactococcuslactisviasurfacedisplayedaffibody
AT berlecales targetingil6byengineeredlactococcuslactisviasurfacedisplayedaffibody